The use of anticholinergic drugs requires careful consideration of patient-specific factors, especially in elderly patients and those with certain underlying health conditions. Elderly patients are more vulnerable to the effects of anticholinergics due to increased permeability of the blood-brain barrier and reduced acetylcholine levels in the CNS. As a result, they are more prone to cognitive impairment, delirium, and memory issues when taking these medications. Additionally, elderly individuals often have multiple conditions that may already require anticholinergic treatment (e.g., COPD, urinary incontinence), increasing their anticholinergic burden and placing them at greater risk for adverse effects.
Patients with dementia also have a relative contraindication to anticholinergic drugs. Dementia is often associated with reduced acetylcholine levels in the brain, and further inhibition of this neurotransmitter can worsen cognitive function. Similarly, individuals with conditions like glaucoma, prostatic hypertrophy, tachyarrhythmias, and hyperthyroidism are at higher risk for complications from anticholinergic drugs. For example, in glaucoma, particularly narrow-angle glaucoma, anticholinergics can exacerbate intraocular pressure, leading to potential vision loss. In patients with tachyarrhythmias or coronary artery disease, the tachycardia induced by anticholinergics may worsen their condition by increasing myocardial oxygen demand and reducing oxygen supply.
Careful consideration of the total anticholinergic burden is necessary when prescribing these medications, particularly in individuals already taking other drugs with anticholinergic properties. Failure to account for cumulative anticholinergic effects can result in an increased risk of adverse effects and toxicity. Serum anticholinergic assays and tools like the Anticholinergic Drug Scale (ADS) can help healthcare providers assess the overall anticholinergic activity in a patient's medication regimen, allowing for more informed prescribing decisions.
